Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oncology Institute (TOI) EBIT (2020 - 2025)

Oncology Institute's EBIT history spans 6 years, with the latest figure at -$6.9 million for Q4 2025.

  • For Q4 2025, EBIT rose 42.1% year-over-year to -$6.9 million; the TTM value through Dec 2025 reached -$36.1 million, up 39.98%, while the annual FY2025 figure was -$36.1 million, 39.98% up from the prior year.
  • EBIT reached -$6.9 million in Q4 2025 per TOI's latest filing, up from -$8.1 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$1.1 million in Q2 2021 to a low of -$40.8 million in Q4 2021.
  • Average EBIT over 5 years is -$15.1 million, with a median of -$14.4 million recorded in 2023.
  • Peak YoY movement for EBIT: plummeted 1540.14% in 2022, then soared 45.32% in 2024.
  • A 5-year view of EBIT shows it stood at -$40.8 million in 2021, then skyrocketed by 38.58% to -$25.1 million in 2022, then surged by 39.04% to -$15.3 million in 2023, then rose by 21.97% to -$11.9 million in 2024, then soared by 42.1% to -$6.9 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's EBIT are -$6.9 million (Q4 2025), -$8.1 million (Q3 2025), and -$11.2 million (Q2 2025).